BridgeBio Pharma, Inc. — Director's Dealing 2025

Aug 18, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK: 0001869105
Period of Report: 2025-08-11

Reporting Person: BridgeBio Pharma LLC (N/A)
Reporting Person: BridgeBio Pharma, Inc. (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13805126	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$3.83	2030-05-18	Common Stock (63934)		Direct
Stock Option (Right to Buy)	$1.02	2030-05-18	Common Stock (9494)		Direct

Footnotes

F1: Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collective, the BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.

F2: (Continued from Footnote 1) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F3: The shares subject to such option are fully vested.